Log In
Print this Print this

actoxumab/bezlotoxumab (MDX-066/MDX-1388) (MK-3415A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of two human mAbs targeting against Clostridium difficile toxins A and B
Molecular Target Clostridium difficile toxin A (TcdA) ; Clostridium difficile toxin B (TcdB)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today